For: | Shi JH, Luo L, Chen XL, Pan YP, Zhang Z, Fang H, Chen Y, Chen WD, Cao Q. Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China. World J Gastroenterol 2020; 26(41): 6455-6474 [PMID: 33244205 DOI: 10.3748/wjg.v26.i41.6455] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v26/i41/6455.htm |
Number | Citing Articles |
1 |
Xiaoxia Dong, Xiaoxiao Chen, Yuxiu Ren. MALT1 reflects inflammatory cytokines, disease activity, and its chronological change could estimate treatment response to infliximab in Crohn's disease patients. Journal of Clinical Laboratory Analysis 2022; 36(10) doi: 10.1002/jcla.24650
|
2 |
Zixuan He, Xianqin Huang, Dingyi Chen, Guoan Wang, Yuezhen Zhu, Huangqianyu Li, Sheng Han, Luwen Shi, Xiaodong Guan. Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review. BMJ Global Health 2023; 8(11): e012780 doi: 10.1136/bmjgh-2023-012780
|
3 |
Jian-Gao Fan, Ying Li, Ze Yu, Xing-Xian Luo, Ping Zheng, Xin Hao, Ze-Yuan Wang, Fei Gao, Guo-Qing Zhang, Wan-Yu Feng. Effectiveness and Economic Evaluation of Polyene Phosphatidyl Choline in Patients With Liver Diseases Based on Real-World Research. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.806787
|